| | Study | Year | Treatment | Control | Number (T/C) | Duration | Results report |
| | Yang and Li [11] | 2016 | Sulfotanshinone IIA (40–80 mg/d, ivgtt, qd) + western standard treatment | Western standard treatment | 96/96 | 21 d | mALB | | Hu [12] | 2017 | Sulfotanshinone IIA (40 mg/d, ivgtt, qd) + valsartan (80 mg/d, po, qd) | Valsartan (80 mg/d, po, qd) | 40/40 | 14 d | Scr | | Ma et al. [9] | 2017 | Sulfotanshinone IIA (60 mg/d, ivgtt, qd) + valsartan (80 mg/d, po, qd) | Valsartan (80 mg/d, po, qd) | 36/36 | 14 d | Scr | | Li and Guo [13] | 2017 | Sulfotanshinone (60 mg/d, ivgtt, qd) + valsartan (200 mg/d, po, qd) | Valsartan (200 mg/d, po, qd) | 100/100 | 14 d | Scr, CysC, 24-hour proteinuria | | Cao et al. [14] | 2014 | Sulfotanshinone IIA (60 mg/d, ivgtt, qd) + irbesartan (150 mg/d, po, qd) | Irbesartan (150 mg/d, po, qd) | 45/44 | 28 d | mALB, 24-hour proteinuria | | Tuxunguli [15] | 2017 | Sulfotanshinone IIA (60 mg/d, ivgtt, qd) + valsartan (80 mg/d, po, qd) | Valsartan (80 mg/d, po, qd) | 64/64 | 14 d | Scr, CysC, 24-hour proteinuria | | Li [16] | 2018 | Sulfotanshinone IIA (60 mg/d, ivgtt, qd) + alprostadil (10 μg/d, iv, qd) | Alprostadil (10 μg/d, iv, qd) | 52/52 | 14 d | BUN, scr, β2-MG | | Gong et al. [17] | 2012 | Sulfotanshinone IIA (40 mg/d, ivgtt, qd) + alprostadil (10 μg/d, iv, qd) | Alprostadil (10 μg/d, iv, qd) | 39/39 | 14 d | BUN, β2-MG | | Li [18] | 2007 | Sulfotanshinone IIA (60 mg/d, ivgtt, qd) + western standard treatment | Western standard treatment | 20/20 | 21 d | Scr, safety | | Gao and Gao [19] | 2011 | Sulfotanshinone IIA (50 mg/d, ivgtt, qd) + western standard treatment | Western standard treatment | 48/42 | 28 d | BUN, Scr,24-hour proteinuria | | Yan et al. [20] | 2011 | Sulfotanshinone IIA (50 mg/d, ivgtt, qd) + western standard treatment | Western standard treatment | 71/59 | 15 d | GFR | | Deng [21] | 2011 | Sulfotanshinone IIA (60 mg/d, ivgtt, qd) + western standard treatment | Western standard treatment | 20/20 | 20 d | CysC, 24-hour proteinuria | | Wang [22] | 2014 | Sulfotanshinone IIA (40 mg/d, ivgtt, qd) + + Alprostadil (10 μg/d, ivgtt, qd) + western standard treatment | Western standard treatment | 32/32 | 28 d | BUN, GFR, safety | | Peng et al. [23] | 2010 | Sulfotanshinone IIA (40 mg/d, ivgtt, qd) + haikun shenxi capsule (6 capsules/d, po, tid) | Western standard treatment | 30/28 | 21 d | BUN, scr | | Wei et al. [24] | 2016 | Sulfotanshinone IIA (40 mg/d, ivgtt, qd) + alprostadil (10 μg/d, ivgtt, qd) | Alprostadil (10 μg/d, ivgtt, qd) | 27/15 | 14 d | BUN | | Xu [25] | 2013 | Sulfotanshinone IIA (50 mg/d, ivgtt, qd) + alprostadil (10 μg/d, ivgtt, qd) | Alprostadil (10 μg/d, ivgtt, qd) | 40/40 | 28 d | Scr | | Wang [26] | 2018 | Sulfotanshinone IIA (50 mg/d, ivgtt, qd) + shen kang injection (100 ml/d, ivgtt, qd) | Western standard treatment | 50/50 | 30 d | 24-hour proteinuria | | Ping [27] | 2007 | Sulfotanshinone IIA (50 mg/d, ivgtt, qd) + prednisone (1 mg/kg/d, po, qd) | Prednisone (1 mg/kg/d, po, qd) | 40/22 | 21 d | BUN | | Chen et al. [28] | 2009 | Sulfotanshinone IIA (100 mg/d, ivgtt, qd) + prednisone (1 mg/kg/d, po, qd) | Prednisone (1 mg/kg/d, po, qd) | 60/60 | 60 d | BUN | | Liao et al. [29] | 2009 | Sulfotanshinone IIA (0.5 mg/kg/d, ivgtt, qd) + western standard treatment | Western standard treatment | 14/14 | 7 d | GFR | | Gu et al. [30] | 2013 | Sulfotanshinone IIA (0.5 mg/kg/d, ivgtt, qd) + western standard treatment | Western standard treatment | 30/30 | 14 d | GFR |
|
|
